NCT06192979 2026-03-09
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Peking University People's Hospital
Phase NA Recruiting
Clinical Trials
32 trialsNCT06627309 2026-03-09
Rapid dFLC Response Predict CHR in AL Amyloidosis
Peking University People's Hospital
Recruiting
NCT04270175 2026-02-27
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT07335887 2026-01-13
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT03618537 2025-12-04
Ixazomib Maintenance Study in Patients With AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05451771 2025-07-08
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Columbia University
Phase 1/2 Recruiting
NCT06455748 2024-06-12
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study
First Affiliated Hospital of Wenzhou Medical University
Phase NA Recruiting
NCT00520767 2023-12-22
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01728259 2023-05-09
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT03252600 2023-01-25
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
Barbara Ann Karmanos Cancer Institute
Phase 2 Unknown
NCT03236792 2022-09-29
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT01849783 2022-05-11
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Phase 2 Completed
NCT04474938 2022-05-10
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
Peking Union Medical College Hospital
Phase 2 Unknown
NCT00981708 2021-04-30
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
University of Athens
Phase 1/2 Completed
NCT02545907 2021-04-15
CATALYST
University College, London
Phase 1/2 Completed
NCT03401372 2021-02-23
BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients
Peking Union Medical College Hospital
Phase NA Completed
NCT01083316 2020-09-25
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT01570387 2020-09-22
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Boston Medical Center
Phase 1/2 Completed
NCT03000660 2020-08-21
Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
Tufts Medical Center
Phase 1 Terminated
NCT01383759 2020-04-07
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01510613 2018-03-12
Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 2 Completed
NCT01194791 2017-04-25
LENDEXAL
PETHEMA Foundation
Phase 2 Completed
NCT00091260 2017-02-20
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT00679367 2017-02-20
MRD
Boston Medical Center
Phase 2 Completed
NCT00458822 2016-08-10
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00477971 2016-05-17
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
Phase 3 Completed
NCT01072773 2014-04-02
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
Mayo Clinic
Phase 2 Completed
NCT01998503 2013-11-29
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Nanjing University School of Medicine
Phase 3 Completed
NCT00564889 2013-05-14
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
Phase 2 Completed
NCT00089167 2013-01-16
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00621400 2011-05-10
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
Nantes University Hospital
Phase 1/2 Completed
NCT00344526 2007-06-28
Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
University Hospital, Limoges
Phase 3 Completed